| |
Lupus is scary; it can be life threatening, life changing and incurable.
But it is also treatable, survivable and, most importantly, many
aspects of the disease can be managed by you - the patient. The
first step is to understand what is happening within and to your
body.
Lupus
means, “wolf.” Erythematosus means
“redness.” In 1851, doctors coined this name for the
disease because they thought the facial rash that frequently accompanies
lupus looked like the bite of a wolf. Lupus can be categorized into
three groups: discoid lupus erythematosus, systemic lupus erythematosus,
and drug-induced systemic
lupus erythematosus.
Discoid
lupus erythematosus (DLE) is characterized by a skin rash
only. It occurs in about 20% of patients with systemic lupus erythematosus.
The lesions are patchy, crusty, sharply defined skin plaques that
may scar. These lesions are usually seen on the face or other sun-exposed
areas. DLE may cause patchy, bald areas on the scalp and hypopigmentation
or hyperpigmentation in older lesions. Biopsy of a lesion will usually
confirm the diagnosis. Topical and intralesional corticosteroids
are usually effective for localized lesions; antimalarial drugs
may be needed for more generalized lesions. DLE rarely progresses
to systemic
lupus erythematosus.
Systemic
lupus erythematosus (SLE, or lupus) is a chronic, inflammatory,
multisystem disorder of the immune system. Lupus: In SLE, the body
develops antibodies that react against the person’s own normal
tissue. This abnormal response leads to the many manifestations
of SLE and can be very damaging. The course is unpredictable and
individualized; no two patients are alike. Lupus is not contagious,
infectious, or a form of cancer. It usually develops in young women
of childbearing years, but many men and children also develop lupus.
African Americans and Hispanics have a higher frequency of this
disease than do Caucasians. SLE also appears in the first-degree
relatives of lupus patients more often than it does in the general
population, which indicates a strong hereditary component. However,
most cases of SLE occur sporadically, indicating that both genetic
and environmental factors play a role in the development of the
disease.
Lupus varies
greatly in severity, from mild cases requiring minimal intervention
to those in which significant and potentially fatal damage occurs
to vital organs such as the lungs, heart, kidney, and brain. The
disease is characterized by “flares” of activity interspersed
with periods of improvement or remission. A flare, or exacerbation,
is increased activity of the disease process with an increase in
physical manifestations and/or abnormal laboratory test values.
Periods of improvement may last weeks, months, or even years. The
disease tends to remit over time. Some patients never develop severe
complications, and the outlook is improving for those patients who
do develop severe manifestations.
Drug-induced
SLE develops after the use of certain drugs and has symptoms
similar to those of SLE. The characteristics of this syndrome are
pleuropericardial inflammation, fever, rash, and arthritis. Serologic
changes also occur. The clinical and serologic signs usually subside
gradually after the offending drug is discontinued. A wide variety
of drugs are implicated in this form of SLE.
| Drugs
with proven association |
| |
- Chlorpromazine
- Hydralazine
- Isoniazid
- Methyldopa
- Procainamide
|
Source: National Institute of Health
|
|
 |